Comparison of fluorodeoxyglucose positron emission tomography and ‘conventional diagnostic procedures’ for the detection of distant metastases in breast cancer patients
- 1 September 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 23 (9) , 857-864
- https://doi.org/10.1097/00006231-200209000-00009
Abstract
The presence of distant metastases is the main prognostic factor in patients with breast cancer and has a significant influence in the choice of therapy. Therefore, chest X-ray, bone scintigraphy and ultrasound of the abdomen are performed to detect distant metastases at diagnosis and follow-up. Fluorodeoxyglucose positron emission tomography (FDG PET) has been shown to provide sensitive detection of primary tumour and metastases for many tumour entities, but little information is available about the diagnostic value for breast cancer patients. This study retrospectively compared FDG PET for detection of metastatic disease with chest X-ray, bone scintigraphy and ultrasound of the abdomen, referred to as ‘conventional diagnostic procedures’ (CDPs), in 50 breast cancer patients. Imaging procedures were analysed in a blinded fashion with the results classified as ‘no evidence of metastases’, ‘equivocal’ and ‘evidence of metastases’. Clinical follow-up and the results of other imaging modalities including computed tomography and magnetic resonance imaging were used to determine if metastases were present. FDG PET identified metastatic disease with a sensitivity and specificity of 86% and 90% as compared to 36% and 95% for CDPs, respectively. Regarding ‘equivocal’ and ‘evidence of metastases’ as positive, the sensitivity of CDPs increased to 57% with a corresponding specificity of 81%, whereas sensitivity and specificity of FDG PET remained unchanged. Regarding different localities of metastases the sensitivity of FDG PET was superior in the detection of pulmonary metastases and especially of lymph node metastases of the mediastinum in comparison to chest X-ray, whereas the sensitivity of FDG PET in the detection of bone and liver metastases was of the same magnitude as compared with bone scintigraphy and ultrasound of the abdomen.Keywords
This publication has 17 references indexed in Scilit:
- Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging proceduresEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and LimitationsJournal of Clinical Oncology, 2000
- Value of Combined FDG PET and MR Imaging in the Evaluation of Suspected Recurrent Local-Regional Breast Cancer: Preliminary ExperienceRadiology, 1999
- Onko-PET: Bildanalyse mittels Monitor versus standardisierter FilmdokumentationNuklearmedizin-Nuclear Medicine, 1999
- Positron Emission Tomography for Diagnosis of Breast TumorsOncology Research and Treatment, 1997
- Assessment of Axillary Lymph Node Involvement in Breast Cancer Patients With Positron Emission Tomography Using Radiolabeled 2-(Fluorine-18)-fluoro-2-deoxy-D-glucoseJNCI Journal of the National Cancer Institute, 1996
- Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancerCancer, 1993
- The Application of Positron Emission Tomographie Imaging With Fluorodeoxyglucose to the Evaluation of Breast DiseaseAnnals of Surgery, 1992
- Micrometastases in breast cancer: Long-term follow-up of the first patient cohortEuropean Journal of Cancer and Clinical Oncology, 1991
- Relation of tumor size, lymph node status, and survival in 24,740 breast cancer casesCancer, 1989